Access our global infectious disease and vaccine experience to fight emerging and re-emerging diseases.
Allucent is ready to partner with you to conduct trials for infectious diseases caused by viruses, bacteria, fungi, or parasites. We’ve been part of the effort against COVID-19, and our extensive experience
provides a significant advantage in proven strategic planning, regulatory guidance, and successful clinical trial execution.
We are particularly experienced in working on government-funded infectious disease and vaccine trials, and were selected by the U.S. Department of Defense as a prime CRO contractor for the Operation Warp Speed effort against COVID-19.
Infectious Disease and Vaccine Experience
It’s important to choose a team that has the right kind of therapeutic experience for your clinical trial. Allucent’s therapeutically aligned, specialized staff have a broad range of expertise in infectious disease and vaccine clinical development and regulations from the U.S., EU, and beyond.
- COVID19 (vaccines/treatment)
- C. difficile
- Pneumonia (CAP, HAP, VAP)
- Hepatitis B
- Hepatitis C
- Influenza A, B, C
- Complicated Intra-abdominal infection
- Complicated skin and skin structure infections
- Urinary tract infection (complicated and non-complicated)
- Tuberculosis Sepsis/septic shock
- Otitis media
- Prosthetic joint infection
- Common cold
- Tinea pedis
- Traveler’s diarrhea
Global Infectious Disease and Vaccine Expertise
Vaccine Development Specialization
Our vaccines development experts have extensive experience designing, implementing, and executing clinical trials involving live attenuated, inactivated, subunit, toxoid, mRNA, and viral vector vaccines for infectious diseases, allergies, immunotherapies, and oncology indications. These include COVID-19, hepatitis B & C, grass, birch, and dust mite allergies, cervical cancer, and melanoma.
Monitoring Strategies for Vaccine Trials
Data-driven, risk-based monitoring solutions, including centralized monitoring, are designed specifically to manage large data volumes upon enrollment of vaccine trials, while ensuring data integrity in remote settings.
Patient Recruitment – Global, Regional, Seasonal
Natural selection of pathogens, diversity of trial participants, and timing are all important site-selection criteria for infectious disease clinical trials. Our global reach, including industry-leading Central and Eastern Europe specialization, provides access to patient populations, site networks, and academic institutions, focused on meeting and exceeding your enrollment goals.
Critical Care Setting Experts
Allucent’s teams have deep expertise in supporting studies in an ICU/critical care setting and navigating the common challenges encountered in this complex environment. That knowledge enables us to provide proactive and insightful CRO services based on proven strategies for indications from pneumonia to COVID-19.
Federal Research CRO Solutions
We have supported federally funded vaccine and infectious disease clinical research programs for more than 20 years. Our proven track record has allowed us to collaborate with multiple government agencies including NIH, DOD, BARDA, and CDC.
Regulatory Strategies and Submissions Team
Whether your new product is a drug, vaccine, biologic, GMO, cell and gene therapy, device, or a combination product, we understand the nuances of regulatory requirements and have the resources and proven expertise to address your specific needs.
Allucent Supporting COVID-19 Research
Allucent stands with the global community in the fight against COVID-19. No other disease in recent history has captured the world like Coronavirus. We are poised to help pharmaceutical and biotechs by rapidly deploying their clinical trials in the search for vaccines and therapies to fight infectious disease.
Our Participation in OWS
We have several ongoing COVID-19 studies and are proud to have been selected by the U.S. Department of Defense as a prime CRO contractor in support of Operation Warp Speed. We continue these efforts through ongoing activities in support of its successor, the Countermeasures Acceleration Group (CAG).
We understand that drug development partners with medical countermeasures (MCM) expertise are crucial in bringing vaccines and treatments to the front lines of the COVID-19 battle. As an MCM-capable CRO, Allucent has the full capabilities to support your initiative.
Seeking Government Funding for Your Project?
Allucent currently holds memberships in the Medical CBRN Defense Consortium (MCDC). We also work with the DoD’s Other Transaction Authority (OTA) and under Other Transactions (OTs).